Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Pharmacogenet Genomics. 2012 Jan;22(1):32–42. doi: 10.1097/FPC.0b013e32834e1641

Table 3.

Results for fixed effects in the mixed-effects model for CYP3A5*3 in the longitudinal data analysis for log-transformed tacrolimus C/D ratio.

Covariate Coefficienta (S.E.) P value
CYP3A5*3 0.54 (0.044) 7.15 × 10−29

Albuminb (x) −0.17 (0.04) 2.07 × 10−5
   (x') 0.12 (0.04) 0.005

Age 0.007 (0.002) 1.80 × 10−5

Weightb (x) −0.007 (0.002) 3.24 × 10−4
   (x') 0.006 (0.002) 0.004

Hemoglobin 0.015 (0.006) 0.012

Days post transplantb (x) 0.0004 (6.2 × 10−5) 2.97 × 10−9
        (x') −0.0012 (2.5 × 10−4) 2.44 × 10−6

Sex (Male vs. Female) 0.034 (0.043) 0.431

Principal components (PCs)
 PC1 −0.85 (0.59) 0.155
 PC2 0.28 (0.40) 0.487
 PC3 −0.34 (0.40) 0.404
 PC4 −0.25 (0.40) 0.535
 PC5 −0.20 (0.40) 0.616
 PC6 −0.74 (0.40) 0.064
 PC7 0.09 (0.40) 0.816
 PC8 −0.27 (0.40) 0.504
 PC9 0.57 (0.40) 0.157
 PC10 0.48 (0.40) 0.228
a

For coefficients with a positive value, the covariate results in an increase in log-transformed tacrolimus C/D ratio, whereas a negative values results in a decrease in log-transformed tacrolimus C/D ratio.

b

Restricted cubic spline functions with 3 knots were used to model nonlinear time trend and relationships, and x and x' are the corresponding linear and nonlinear terms.